Rift, an early stage research and development company, developing first-in-class antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cells microenvironment.
RIFT Biotherapeutics
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.riftbio.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address6335 Nancy Ridge Drive, Suite R, CA, 92121San DiegoUnited States
6335 Nancy Ridge Drive, Suite R, CA, 92121
San Diego
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/rift-biotherpeutics” connections=”true” suffix=””]
In Mar 2017, SalvaRx investd US$1 Mn in Rift and acquired approx 30% equity in company. Also, Subject to Rift achieving certain development milestones with this initial funding, SalvaRx has the option to invest up to an additional US$1.5 Mn at the same valuation and to acquire all outstanding shares of Rift in exchange for new shares in SalvaRx on the same basis.